Guy Brusselle, MD, PhD, explains why broader cytokine blockade with dupilumab outpaced omalizumab, and why nonremitters in EVEREST still improved.
Guy Brusselle, MD, PhD
Advertisement
Guy Brusselle, MD, PhD, of Ghent University Hospital.
Articles by Guy Brusselle, MD, PhD
Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
eGFR Underestimates CKD in Patients with Cancer, Study Finds
2
The HCPFive: Top News for Healthcare Providers from the Week of 10/18
3
42% on Povetacicept Reach KDIGO-Aligned UPCR Target in RAINIER
4
Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant
5